US Dermatologic Clinical Summit
The U.S. Dermatologic Clinical Summit is a dynamic, two-day, live CME event designed for dermatologists and advanced practice providers seeking practical, evidence-based insights across medical, surgical, and procedural dermatology. Through expert-led lectures, case-based discussions, interactive workshops, and focused product theaters, attendees will gain actionable strategies to enhance clinical outcomes, optimize practice operations, and stay ahead of emerging therapies and technologies. This immersive in-person experience also offers meaningful networking opportunities in a collaborative, practice-forward environment.
Target Audience
This activity is designed for an audience of physicians, physician assistants, nurse practitioners and nurses.
Learning Objectives
- Apply evidence-based diagnostic and treatment strategies for common and complex medical, surgical, and pediatric dermatologic conditions.
- Integrate emerging therapies and technologies—including biologics, oral agents, devices, injectables, regenerative medicine, and AI—into dermatologic practice.
- Improve procedural outcomes and patient safety through best practices in surgical techniques, postoperative management, and risk mitigation.
- Utilize case-based reasoning to manage challenging dermatologic presentations, including alopecia, inflammatory disease, and diagnostic mimickers.
- Enhance practice performance and compliance through improved documentation, coding accuracy, medicolegal risk awareness, and interdisciplinary collaboration.
- Identify opportunities for professional development and team-based care across dermatologists, PAs, and NPs to optimize patient outcomes.
Commercial Support
There is no commercial support for this activity.
DISCLOSURES | ||
Name | Relationship | Commercial Interest |
Lindsay Ackerman, MD | Advisor
Consultant
Speaker | Eli-Lilly, Lill ICOS LLC, AbbVie, Bristol-Myers Squibb, Novartis, Sanofi, Timber Pharmaceuticals, Janseen Pharmaceuticals, Inc., UCB
AbbVie, Lilly ICOS LLC
AbbVie, Amgen, arGEN-X, Bristol-Myers Squibb, Eli Lilly, Helsinn Healthcare, Kyowa Kirin, Lilly ICOS LLC, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Galderma
Topics: Atopic dermatitis, Psoriasis, Cutaneous lymphoma, Alopecia areata, Bullous Pemphigoid, Congenital ichthysis, Psoriasis sciatica |
David Cotter, MD, PhD | Advisor
Consultant
Speaker | Eli-Lilly, LEO
Eli-Lilly, LEO
AbbVie, Arcutis, Bristol Myers Squibb, Castle Biosciences, Dermavant/Organon, Galserma, LEO, Novartis, Sanofi, Regeneron
Topics: Atopic dermatitis, Prurigo Nodularis, Chronic Spontaneous Uticaria, Bullous Pemphigoid, Acne, Rosacea, Psoriasis, Seborrheic dermatitis |
Fred Ghali, MD | Advisor
Individual stocks and stock options
Researcher
Speaker | Sanofi, Regeneron, Oreganon, Arcutis, Galderma
Top MD, Inc.
Incyte, Arcutis, Eli Lilly, Dermavant
Sanofi, Regeneron, Arcutis, Abbvie, Oreganon, Inctye, L’Oreal
Topics: Atopic Dermatitis, Alopecia, Vitiligo, Moisturizers |
Jennifer Holman, MD, FAAD | N/A | Nothing to disclose |
Jonathan Lee, MD | N/A | Nothing to disclose |
George Martin, MD | Ownership Interest | Scholars in Medicine
Topics: AI in clinical decision making |
Victoria Shelton, BHA | N/A | Nothing to disclose |
Linda Stein Gold, MD | Advisor | AbbVie, Amgen, Arcutis, J&J, Takeda, Lilly, Organon, Alumis
Topics: Psoriasis |
Daniel Walker, MD | Speaker | AbbVie, Topic: Eczema |
Jacqueline Watchmaker, MD | Advisor
Consultant | Allergan, Loreal
Shark Ninja
Topics - Skincare |
Dustin Wilkes, Doctor of Osteopathic Medicine | N/A | Nothing to disclose |
Karin Williamson | N/A | Nothing to disclose |
Dorothy Caputo, MA, BSN, RN President, AKH Inc., Advancing Knowledge in Healthcare | N/A | Nothing to disclose |
Bernadette Makar, MSN, APRN-BC, NP-C (planner/reviewer) | N/A | Nothing to disclose |
AKH Inc Staff and Planners | N/A | Nothing to disclose |
Revive Staff and Planners | N/A | Nothing to disclose |
All of the relevant financial relationships listed for these individuals have been mitigated. | ||
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and REVIVE™ Institute and Training. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 8.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 8.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing
Credit being awarded: 8.0 ANCC contact hours
Physician Associates
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 8.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and REVIVE™ Institute and Training. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 8.0 contact hour(s) (which includes 0.0 hour(s) of pharmacology).
Available Credit
- 8.00 AANP
- 8.00 AAPA Category 1 CME
- 8.00 AMA PRA Category 1 Credit™
- 8.00 ANCC
- 8.00 Attendance

Facebook
X
LinkedIn
Forward